Accretion Pharmaceuticals SME IPO Details
| Detail | Description |
|---|---|
| IPO Date | May 14, 2025 to May 16, 2025 |
| Listing Date | - |
| Face Value | ₹ 10 per share |
| Issue Price Band | ₹ 96 to ₹ 101 per share |
| Lot Size | 1,200 Shares |
| Total Issue Size | 29,46,000 shares (aggregating up to ₹ 29.75 Cr) |
| Fresh Issue | 29,46,000 shares (aggregating up to ₹ 29.75 Cr) |
| Issue Type | Bookbuilding IPO |
| Listing At | NSE SME |
| Share Holding Pre Issue | 81,70,000 shares |
| Share Holding Post Issue | 1,11,16,000 shares |
| Market Maker Portion | 1,47,600 shares |
About Accretion Pharmaceuticals SME IPO
Accretion Pharmaceuticals is launching a SME Book‑Building IPO on NSE EMERGE, having filed its DRHP on January 8, 2025. The issue comprises up to 3,000,000 equity shares of ₹10 face value, with the exact price band yet to be announced. The company posted a turnover of ₹13.35 cr and PAT of ₹1.49 cr for FY 2023‑24, translating into an annualized revenue run‑rate of ₹35.7 cr and PAT run‑rate of ₹4.7 cr. Proceeds will fund capex, working capital and debt repayment. Promoters hold 96.28% pre‑issue.
Introduction
Accretion Pharmaceuticals Limited (“Accretion Pharma”) is set to tap the SME platform of the National Stock Exchange (NSE EMERGE) via a Book‑Building IPO. This marks the first public equity offering by the company since its conversion from a partnership into a public limited company in November 2023. The IPO will help the company scale up manufacturing capacity, upgrade facilities, shore up working capital and pare down borrowings — key steps for a fast‑growing pharma contract manufacturer.
Company Overview
Business Model & Operations
- Manufacturing footprint: Tablets, capsules, oral liquids, external preparations (ointments, gels, lotions, medicated shampoos) and oral powders (sachets, dry syrups).
- Revenue streams: Direct sales of in‑house formulations; contract manufacturing and loan‑licence manufacturing for third‑party marketers on a principal‑to‑principal basis.
- Certifications: ISO 9001:2015 (QMS), ISO 14001:2015 (EMS) and ISO 22000:2018 (Food Safety)
- Geographical reach: Present in 20+ countries, with plans to expand further.
Management & Shareholding
- Promoters: Harshad N. Rathod, Hardik M. Prajapati, Mayur P. Sojitra and Vivek A. Kumar Patel (collectively hold 96.28% pre‑issue).
- Board composition: Mix of promoter directors and independent professionals, fulfilling SEBI’s corporate governance norms for SMEs.
Objectives of the Issue
According to the Draft Red Herring Prospectus, net IPO proceeds will be deployed to:
- Capital expenditure towards purchase of new equipment and machinery.
- Upgradation of existing manufacturing facility to enhance capacity and technology.
- Repayment/prepayment of certain borrowings to optimize the balance sheet.
- Funding working capital requirements to support higher raw‑material procurement and inventory.
- General corporate purposes, including product registrations in overseas markets.
Conclusion
Accretion Pharmaceuticals’ SME IPO offers an entry into a certified contract-manufacturing play with modest financials but clear growth intent. The use of proceeds towards capacity expansion and working-capital strengthening fits the company’s stated growth trajectory. Investors should watch the final price band and peer valuations before deciding.
Accretion Pharmaceuticals SME IPO Financial Information
Latest Revenue
₹ 11.89 Cr
Profit After Tax
₹ 1.57 Cr
Net Worth
₹ 9.91 Cr
| Period Ended | Assets | Revenue From Operations | Profit After Tax | Net Worth | Total Borrowing |
|---|---|---|---|---|---|
| 30 Sep 2024 | 29.34 | 11.89 | 1.57 | 9.91 | — |
| 31 Mar 2024 | 27.05 | 33.94 | 3.88 | 5.35 | — |
| 31 Mar 2023 | 20.58 | 29.53 | 0.1 | 3.84 | — |
| 31 Mar 2022 | 17.74 | 22.58 | 0.08 | 3.08 | — |
| Amount in ₹ Crore | |||||
Accretion Pharmaceuticals SME Key Performance Indicator
| KPI | Values |
|---|---|
| ROE | 25.20% |
| ROCE | 11.73% |
| Debt/Equity | 2.52 |
| RoNW | 72.47% |
| PAT Margin | 11.51 |
| Price to Book Value | 7.55 |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (Rs) | 4.74 | 2.82 |
| P/E (x) | 21.29 | 35.82 |
Recommended Advisory Services
Ready to take your company public? Explore our specialized IPO advisory services tailored for Indian enterprises.
The INDIA IPO Publication is managed by an editorial team that includes highly experienced finance journalists, market researchers and professionals from the capital markets industry who strive to create high-quality content based on credible sources. Our editors write about IPOs, capital markets, corporate news, capital-raising strategies, regulations and other business matters to ensure our audience stays updated with the latest information. We conduct detailed research and fact-check all information before publishing any content to ensure credibility.
Competitive Strengths
1. Certified, High Quality Manufacturing
2. Scale & Infrastructure
3. Diversified Product & Client Base
4. Global Footprint & Growth Culture
5. Strong Promoter Commitment
Download regulatory filings
Accretion Pharmaceuticals SME IPO Timeline
| IPO Open Date | Wed, May 14, 2025 |
| IPO Close Date | Fri, May 16, 2025 |
| Tentative Allotment | Mon, May 19, 2025 |
| Initiation of Refunds | Tue, May 20, 2025 |
| Credit of Shares to Demat | Tue, May 20, 2025 |
| Tentative Listing Date | Wed, May 21, 2025 |
| Cut-off time for UPI mandate confirmation | 5 PM on May 16, 2025 |
IPO Lot Size
| Investors | No.of lots | Shares Offered | Max Bid Amount |
|---|---|---|---|
| Retail (Min) | 1 | 1,200 | ₹ 1,21,200 |
| Retail (Max) | 1 | 1,200 | ₹ 1,21,200 |
| HNI (Min) | 2 | 2,400 | ₹ 2,42,400 |